Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $67.7 million.

  • Pulse Biosciences' Shares Outstanding rose 1011.44% to $67.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year increase of 1011.44%. This contributed to the annual value of $65.9 million for FY2024, which is 1955.24% up from last year.
  • Latest data reveals that Pulse Biosciences reported Shares Outstanding of $67.7 million as of Q3 2025, which was up 1011.44% from $67.3 million recorded in Q2 2025.
  • Over the past 5 years, Pulse Biosciences' Shares Outstanding peaked at $67.7 million during Q3 2025, and registered a low of $29.7 million during Q4 2021.
  • For the 5-year period, Pulse Biosciences' Shares Outstanding averaged around $50.9 million, with its median value being $55.1 million (2023).
  • Its Shares Outstanding has fluctuated over the past 5 years, first skyrocketed by 4809.72% in 2023, then surged by 83.44% in 2024.
  • Quarter analysis of 5 years shows Pulse Biosciences' Shares Outstanding stood at $29.7 million in 2021, then grew by 25.3% to $37.2 million in 2022, then surged by 48.1% to $55.1 million in 2023, then increased by 19.55% to $65.9 million in 2024, then rose by 2.75% to $67.7 million in 2025.
  • Its Shares Outstanding was $67.7 million in Q3 2025, compared to $67.3 million in Q2 2025 and $67.3 million in Q1 2025.